THE KON-LIN LETTER INITIATES NEW
COVERAGE OF CYTOMEDIX IN ITS FEBRUARY 2008 ISSUE WITH INITIAL TARGET
OF $4.50-$5.00 AND ULTIMATE TARGET OF $7-$9
Rockville, MD, Feb. 12, 2008 – Cytomedix, Inc. (AMEX:
GTF) today announced that the Kon-Lin Letter, a
subscription-based stock market advisory service, has initiated coverage of the Company in its February 2008
newsletter with an initial price target of $4.50-$5.00 per share and an ultimate target of $7.00-$9.00.
Kon-Lin is a 40-year-old publication that provides fundamental and technical analysis of individual stocks and
market movements. The Kon-Lin letter is provided as a subscription service only.
ABOUT CYTOMEDIX
Cytomedix, Inc. is a biotechnology company specializing in processes and products derived from
autologous platelet releasates for uses on chronic wounds and other applications. The current offering is
the AutoloGel™ System, a process that utilizes an autologous platelet gel
composed of multiple growth factors, other platelet releasates, and fibrin matrix and is intended for use on
diabetic ulcers, pressure ulcers, leg ulcers and mechanically or surgically debrided wounds. Additional
information regarding Cytomedix is available at: http://www.cytomedix.com.
SAFE HARBOR STATEMENT
Statements contained in this press release not relating to historical facts are forward-looking statements that are
intended to fall within the safe harbor rule for such statements under the Private Securities Litigation Reform Act of
1995. Please note that any opinions, estimates or forecasts regarding Cytomedix’s performance made by the Kon-
Lin Letter are made only by the Kon-Lin Letter and do not represent opinions, forecasts or predictions of
Cytomedix or its management. Cytomedix does not by its reference above imply its endorsement of or concurrence
with such information, conclusions or recommendations. The Kon-Lin Letter is prepared by an independent thirdparty
without the participation of or review by Cytomedix or its management. The Company takes no responsibility
for the opinions or accuracy of the Kon-Lin Letter, and states further that Cytomedix’s actual results may differ
materially from any opinions, estimates or forecasts from any source due to a number of factors, many of which are
beyond Cytomedix’s ability to predict or control, including among others, the success of new sales intiatives,
governmental regulation, acceptance by the medical community and competition. These forward-looking
statements are subject to known and unknown risks and uncertainties that could cause actual events to differ from
the forward-looking statements. More information about some of these risks and uncertainties may be found in the
reports filed with the Securities and Exchange Commission by Cytomedix, Inc.
|
